Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19
Status:
Terminated
Trial end date:
2021-05-12
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of baricitinib in combination with antiviral therapy
for the treatment of patients with moderate or severe coronavirus disease-2019 (COVID-19).
Treatment with antiviral medications such as hydroxychloroquine, lopinavir/ritonavir, and/or
remdesivir may act against infection caused by the virus responsible for COVID-19.
Baricitinib may reduce lung inflammation. Giving baricitinib in combination with antiviral
therapy may reduce the risk of the disease from getting worse and may help prevent the need
for being placed on a ventilator should the disease worsen compared to antiviral therapy
alone.